Table 2 Overall and disease-free survival according to genotypes of two polymorphisms in the combined cohorts.

From: Genetic variants in histone modification regions are associated with the prognosis of lung adenocarcinoma

Polymorphism/genotypese

No. of cases (%)a

Overall survival

Disease-free survival

No. of events (%) b

5Y-OSR (%)c

HR (95% CI)d

Pd

No. of events (%)c

5Y-DFSR (%)c

HR (95% CI)d

Pd

rs17583

CC

173 (43.8)

48 (27.8)

58

1.00

 

79 (45.7)

43

1.00

 

CT

178 (45.1)

31 (17.4)

71

0.48 (0.31–0.76)

0.002

80 (44.9)

37

0.80 (0.58–1.10)

0.16

TT

44 (11.1)

8 (18.2)

59

0.51 (0.24–1.09)

0.08

11 (25.0)

67

0.38 (0.20–0.71)

0.003

Dominant

222 (56.2)

39 (17.6)

69

0.49 (0.32–0.75)

0.001

91 (41.0)

42

0.71 (0.52–0.96)

0.03

Recessive

351 (88.9)

79 (22.5)

65

0.74 (0.35–1.54)

0.42

159 (45.3)

41

0.43 (0.23–0.79)

0.007

Codominant

   

0.60 (0.42–0.85)

0.004

  

0.69 (0.54–0.88)

0.003

rs4751162

AA

273 (68.9)

58 (21.3)

66

1.00

 

107 (39.2)

47

1.00

 

AG

108 (27.3)

28 (25.9)

60

1.30 (0.82–2.05)

0.27

55 (50.9)

35

1.45 (1.04–2.01)

0.03

GG

15 (3.8)

2 (13.3)

60

0.63 (0.15–2.63)

0.53

9 (60.0)

31

2.23 (1.11–4.48)

0.03

Dominant

123 (31.1)

30 (24.4)

60

1.21 (0.78–1.89)

0.40

64 (52.0)

35

1.53 (1.11–2.09)

0.008

Recessive

381 (96.2)

86 (22.6)

64

0.59 (0.14–2.45)

0.47

162 (42.5)

43

2.02 (1.01–4.04)

0.05

Codominant

   

1.09 (0.75–1.58)

0.65

  

1.47 (1.13–1.90)

0.004

  1. aColumn percentage.
  2. bRow percentage.
  3. cFive year-overall survival rate (5Y-OSR) and 5 year-disease free survival rate (5Y-DFSR), proportion of survival derived from Kaplan–Meier analysis.
  4. dHazard ratios (HRs), 95% confidence intervals (CIs) and corresponding P-values were calculated using multivariate Cox proportional hazard models, adjusted for age, gender, smoking status, pathologic stage and adjuvant therapy.
  5. eGenotype failure: nine cases for the rs17583 and eight cases for the rs4751162.
Back to article page